MoonLake Immunotherapeutics Class A MLTX 深 沪
已收盘 02-06 16:00:00 美东时间
15.515
+0.745
+5.04%
华盛通- 最 高18.80
- 今 开14.90
- 成交量 48.93万股
- 最 低 11.06
- 昨 收 14.77
- 总市值 57.29万
- 52周最高 62.75
- 市盈率 静 --
- 换手率 1325.16%
- 52周最低 5.95
- 委 比 8.68%
- 总股本 3.69万
- 历史最高 64.98
- 量 比 0.42
- 振 幅 52.40%
- 历史最低 0.00
- 每 手 1
- 风险率 16.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MoonLake Immunotherapeutics Announces FDA Grants Fast Track Designation For Sonelokimab To Treat Moderate‑To‑Severe Palmoplantar Pustulosis
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that the FDA has granted
02-02 21:02
Goldman Sachs Downgrades MoonLake to Sell, Raises Price Target to $10
Goldman Sachs analyst Richard Law downgrades MoonLake (NASDAQ:MLTX) from Neutral to Sell and raises the price target from $8 to $10.
01-15 17:24
默沙东(MRK)洽谈以超30亿美元收购生物技术公司MoonLake(MLTX)
金吾财讯 | 据外媒报道，默沙东(MRK)今年早些时候曾向生物科技公司MoonLake Immunotherapeutics(MLTX)提出收购要约。报道称，默沙东提出了一份金额超30亿美元的非约束性报价，但初步报价遭到拒绝。三位知情人士透露，两家公司之间的谈判仍有可能重启。外媒称，默沙东在 MoonLake 核心药物公布后期临床数据前主动接洽，凸显后者在被收购谈判中的强势地位。报道同时提到，目前无法保证交易最终达成，且不排除其他买家介入的可能性。
2025-06-03 23:15
默沙东超30亿美元收购邀约遭拒 MoonLake盘后飙涨20%
《金融时报》在美东时间周一报道称，制药巨头默沙东(MRK.US)今年早些时候曾向生物科技公司MoonLake Immunotherapeutics(MLTX.US)提出收购要约。消息发布后，MoonLake股价在美股盘后交易中大幅飙升，一度暴涨超30%，截至发稿，该股上涨约20%。 报道称，默沙东提出了一份金额超30亿美元的非约束性报价，但初步报价遭到拒绝。三位知情人士透露，两家公司之间的谈判仍有可能重启。 《金融时报》分析称，默沙东在 MoonLake 核心药物公布后期临床数据前主动接洽，凸显后者在被收购谈判中的强势地位。报道同时提到，目前无法保证交易最终达成，且不排除其他买家介入的可能性。...
2025-06-03 07:33
Needham Reiterates Buy on MoonLake, Maintains $62 Price Target
Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $62 price target.
2024-09-12 17:55
Cantor Fitzgerald Reiterates Overweight on MoonLake
Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:MLTX) with a Overweight.
2024-09-10 01:18
Sector Update: Health Care Stocks Ease
04:03 PM EDT, 08/26/2024 (MT Newswires) -- Health care stocks eased Monday with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.1%. The iShares Biotechnology ETF (IBB) fell 0.1%. In corporate news, Medirom Healthcare Technologies (MRM) shares more than double...
2024-08-27 04:03
MoonLake Immunotherapeutics Shares Fall After Wolfe Research Downgrade
02:40 PM EDT, 08/26/2024 (MT Newswires) -- MoonLake Immunotherapeutics (MLTX) shares fell 2.1% in recent Monday trading after Wolfe Research downgraded the company's stock to peer perform from outperform. Trading volume stood at about 68,000 shares against a daily average of more than 344,000. Price...
2024-08-27 02:40
Wolfe Research Downgrades MoonLake Immunotherapeutics to Peer Perform From Outperform
06:05 AM EDT, 08/26/2024 (MT Newswires) -- MoonLake Immunotherapeutics (MLTX) has an average outperform rating and a price target range of $55 to $104, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in Nort...
2024-08-26 18:05
